Keybank National Association OH Takes $237,000 Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Keybank National Association OH purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 9,790 shares of the company's stock, valued at approximately $237,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 1,100 shares during the period. Smartleaf Asset Management LLC raised its position in shares of Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after purchasing an additional 1,413 shares during the period. US Bancorp DE grew its position in shares of Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock valued at $47,000 after purchasing an additional 1,508 shares during the period. Finally, Venturi Wealth Management LLC bought a new stake in Hims & Hers Health during the 4th quarter worth approximately $48,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 78,127 shares of the company's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $29.62, for a total value of $2,314,121.74. Following the transaction, the chief executive officer now directly owns 109,956 shares in the company, valued at $3,256,896.72. The trade was a 41.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Michael Chi sold 7,500 shares of the firm's stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $26.00, for a total transaction of $195,000.00. Following the sale, the insider now owns 193,601 shares of the company's stock, valued at approximately $5,033,626. This represents a 3.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 969,191 shares of company stock valued at $34,005,375 over the last 90 days. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Trading Up 0.6 %

NYSE:HIMS opened at $34.68 on Wednesday. The stock has a market capitalization of $7.70 billion, a PE ratio of 78.81 and a beta of 1.37. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The firm has a fifty day simple moving average of $38.03 and a 200 day simple moving average of $27.86.

Remove Ads

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of research reports. Truist Financial lifted their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a "hold" rating in a research note on Wednesday, February 26th. Morgan Stanley lowered shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their target price for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Bank of America reissued an "underperform" rating and issued a $21.00 price target on shares of Hims & Hers Health in a research note on Thursday, March 6th. Canaccord Genuity Group increased their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Finally, Piper Sandler boosted their target price on Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a research note on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and a consensus target price of $37.23.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.